Compounds > 4-(2-(4-isopropylbenzamido)ethoxy)benzoic acid
Page last updated: 2024-12-10

4-(2-(4-isopropylbenzamido)ethoxy)benzoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-(2-(4-isopropylbenzamido)ethoxy)benzoic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3081027
CHEMBL ID4541438
SCHEMBL ID10495017
MeSH IDM0162577

Synonyms (18)

Synonym
113079-40-6
benzoic acid, 4-(2-((4-(1-methylethyl)benzoyl)amino)ethoxy)-
4-(2-(4-isopropylbenzamido)ethoxy)benzoic acid
ns-1
oco-1112
pbab acid
4-[2-[(4-propan-2-ylbenzoyl)amino]ethoxy]benzoic acid
4-[2-(4-isopropylbenzamido)ethoxy]benzoic acid
ODLDHXPJRGNTPC-UHFFFAOYSA-N
SCHEMBL10495017
DTXSID90150280
Z1149820700
AKOS033112450
4-(2-{[4-(propan-2-yl)phenyl]formamido}ethoxy)benzoic acid
CS-0259229
CHEMBL4541438
EN300-72673
ns 1

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" After the bolus injection, the PBAB concentrations in the plasma decreased rapidly, then increased to a peak concentration at 4 hr."( Pharmacokinetic analysis of enterohepatic circulation of 4-[2-(4-isopropylbenzamido)ethoxy]benzoic acid. Effect of intramolecular rearrangement of its acyl glucuronide.
Fukui, H; Komura, H; Morino, A; Sasaki, H, )		0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (11.11)18.7374
1990's1 (11.11)18.2507
2000's3 (33.33)29.6817
2010's0 (0.00)24.3611
2020's4 (44.44)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.29 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carbamates
[no description available]		2.0310amino-acid anion
hydrogen
Hydrogen: The first chemical element in the periodic table with atomic symbol H, and atomic number 1. Protium (atomic weight 1) is by far the most common hydrogen isotope. Hydrogen also exists as the stable isotope DEUTERIUM (atomic weight 2) and the radioactive isotope TRITIUM (atomic weight 3). Hydrogen forms into a diatomic molecule at room temperature and appears as a highly flammable colorless and odorless gas.. dihydrogen : An elemental molecule consisting of two hydrogens joined by a single bond.		2.0310elemental hydrogen;
elemental molecule;
gas molecular entity		antioxidant;
electron donor;
food packaging gas;
fuel;
human metabolite
phosphites
Phosphites: Inorganic salts or organic esters of phosphorous acid that contain the (3-)PO3 radical. (From Grant & Hackh's Chemical Dictionary, 5th ed). phosphite(3-) : A trivalent inorganic anion obtained by removal of all three protons from phosphorous acid.		2.0310phosphite ion;
trivalent inorganic anion
organophosphonates
hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.		2.0310divalent inorganic anion;
phosphite ion
u 0126
U 0126: protein kinase kinase inhibitor; structure in first source		2.4110aryl sulfide;
dinitrile;
enamine;
substituted aniline		antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
osteogenesis regulator;
vasoconstrictor agent
ConditionIndicatedRelationship StrengthStudiesTrials
Breast Cancer
[description not available]		02.610
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.610
Aortic Diseases
Pathological processes involving any part of the AORTA.		01.9810
Arteriosclerosis
Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.		01.9810